Karyopharm Therapeutics was upgraded on November 10, 2014 from “Perform” to “Outperform” by Oppenheimer. Oppenheimer currently has a $53.00 target price on the stock which points to a potential upside of 25.77% from the stock’s previous close.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Other Firms Covering Karyopharm Therapeutics
- Barrington Research – BUY – $54 price target
- Wedbush – outperform – $50 price target
- MLV & Co. – BUY – $54 price target